Cornish brewery wins two gold medals at national beer awards

A Cornish brewery has won two gold medals at a national beer awards event.
Castle Brewery, was awarded two medals at the Society of Independent Brewers (SIBA) National Beer Awards, which were held in Liverpool on March 20, 2025.
The awards are regarded as one of the most significant accolades in UK independent brewing and are judged by a panel of industry experts, brewers, and beer sommeliers.
Castle Brewery's award-winning beers were New Season, a Belgian Pale Ale, and Gorse, a mixed fermentation ale brewed using a native yeast culture captured from the Cornish landscape.
New Season was awarded gold in the Bottled/Canned Continental Ale category, while Gorse was awarded gold in the Bottled/Canned Sour and Wild Ale category.
This marks the second national gold medal award for New Season.
The brewery, which is based in Lostwithiel, has now launched a new brand called Coldframe Brewery, which will separate Castle's continental-inspired beers from its traditional British ales.
Coldframe will build on the stylistic direction of this year's national gold medal-winning beers, New Season and Gorse.
Simon Court, head brewer and owner of Castle and Coldframe Brewery, said: "Coldframe Brewery is the natural evolution of everything we've been working towards.
"Last week's awards were an incredible honour and testament to our vision for the new brewery.
"Coldframe represents our deepening commitment to brewing beers that are shaped by the land, using raw and locally sourced ingredients.
"Everything we are doing is another step closer to becoming the farmhouse brewery we have always aspired to be."
The SIBA National Beer Awards are among the most respected beer competitions in the UK, celebrating the best in independent brewing.
The awards feature rigorous judging by industry professionals, including brewers, beer sommeliers, and expert tasters.
Winning a SIBA Gold Medal can be regarded as a mark of outstanding brewing quality and places.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Boston Globe

3 days ago

• Boston Globe

David H. Murdock, a fierce rags-to-riches corporate raider, dies at 102

He gained a reputation as a relentless and often ruthless turnaround specialist who didn't hesitate to lay off thousands of workers, slash benefits, and make deep cuts in order to reshape and sell a company. He would look for companies with what he deemed 'undervalued assets,' swoop in, make necessary if painful changes, and then sell the entity at a significant profit. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In his oft-stated quest to build the largest private financial empire in the United States, Mr. Murdock took on powerful unions and dominant corporate chieftains, among them Armand Hammer of Occidental Petroleum, and emerged as one of the richest, most successful corporate investors in the nation. In April, Forbes estimated his fortune at $3.7 billion. Advertisement His lack of formal education and humble beginnings fueled his determined rise to wealth and power. In a 1983 interview with The Wall Street Journal, he said: 'Nobody is satisfied with what he has. We were brought on earth to achieve. As long as we want to achieve, we're alive. If we're satisfied, we're already half dead.' Advertisement Well into his 90s, he continued to achieve, serving as chair and CEO of Dole and its parent company, Castle & Cooke, for several decades. 'I never had a boss in my whole life,' he told The New York Times Magazine in 2011. 'I've totally destroyed anybody's ability to tell me what to do.' It was his purchase in 1985 of Castle & Cooke, a venerable and nearly bankrupt Hawaiian agricultural concern, that fueled his ascent as a corporate takeover artist. Castle & Cooke, which had introduced Hawaiian pineapples to the American mainland, provided him with significant land holdings in Hawaii, including Lanai, the sparsely populated and sixth-largest Hawaiian island, home to a vast pineapple plantation. Over time, he turned Castle & Cooke into a successful real estate developer, separating it from its Dole subsidiary. In 2012, he took in hundreds of millions of dollars by selling Lanai to Oracle CEO Larry Ellison. But it was Dole, which Mr. Murdock rebuilt into one of the world's largest sellers of fruit and vegetables, that exemplified his business prowess. He ran Dole for more than 30 years, piling up enormous profits year after year through its global reach, with world headquarters in Dublin and US headquarters in Charlotte, N.C. His only major setback came in 2015, when a Delaware judge ruled that in taking the company private in 2013, Mr. Murdock and its chief operating officer had fraudulently driven down Dole's stock price so that he could buy the business at a cheaper price. The two men were ordered to reimburse shareholders $148 million. Advertisement Mr. Murdock used Dole's profits in the late 2000s to build a $500 million food research center in Kannapolis, N.C., northeast of Charlotte. Its central mission was to study how plant-based diets might lead to longer lives. Married five times, Mr. Murdock was especially devoted to his German-born third wife, Gabriele Murdock, whom he married in 1967. The couple had two sons, and Mr. Murdock adopted a son from his wife's previous marriage. Nearly 20 years her senior, he was devastated when she received a diagnosis of advanced ovarian cancer in 1983. When she died in 1985 at 43, Mr. Murdock had become convinced that lifestyle and diet had contributed to her cancer, and he became obsessed with finding a healthy and sustainable nutrition regimen for himself and for the world. 'If I had known what I know today, I could have saved my wife's life,' he said in the Times Magazine profile, by Frank Bruni. Beginning in his 60s, Mr. Murdock began a quest to change his diet, eating only fruits and vegetables and occasionally fish, eliminating sugar and dairy. 'He wants to reach 125,' Bruni wrote, 'and sees no reason he can't, provided that he continues eating the way he has for the last quarter-century: with a methodical, messianic correctness that he believes can, and will, ward off major disease and minor ailment alike.' David Howard Murdock was born April 11, 1923, in Kansas City, Mo., the middle child and only son of Merte Floyd Murdock, a traveling salesman, and Ruth Gweneth Murdock, who took in laundry and scrubbed floors to help support the family. When David was very young, his father moved the family to Montgomery Township, Ohio, where the boy, who was dyslexic, struggled in school. His learning disabilities made school nightmarish for him. He was taunted and managed only D's, and at age 14 he quit school, just two months into the 10th grade. He was 17 when his mother died of cancer at 42, a loss that haunted him throughout his life. He began working at a service station pumping gas until he was drafted into the Army in 1943. Advertisement After leaving the military at 22, he landed in Detroit penniless. For a time he lived in a park, sleeping under a bush. With the help of a loan company employee he had met in a Detroit diner, he managed to secure $1,200 in loans to buy the diner. He spruced it up, sold it for a small profit and set out for California. He got as far as Phoenix, where he encountered a young city exploding with an influx of postwar transplants. He began to buy up cheap land and build affordable houses for the new arrivals. 'I was building as fast as I could break ground,' he said in the Times Magazine article. 'Bang, bang, bang: I could hardly get a house finished before it was sold.' In 1968, after 17 profitable years, he set off for Los Angeles, where he continued to build, but this time he took on much larger projects, including office buildings. He began investing large stakes in public companies and eventually bought whole companies rather than just stock. In 1974, he acquired Pacific Holding Co. after leading a group of dissident shareholders in a takeover. He took the company private in 1978. That same year, he acquired 19 percent of the shares in Iowa Beef Processor, which he then exchanged for 2.8 percent of the shares in Armand Hammer's Occidental Petroleum, at the time the world's largest independent oil company. Advertisement By 1981, Mr. Murdock had become the largest shareholder of Occidental and began to bang heads with the dynamic Hammer. There was talk that he was angling to succeed Hammer when Hammer retired -- rumors that Mr. Murdock denied. He continued to focus on acquiring stakes in a wide range of companies. Mr. Murdock was not shy about flaunting his wealth. He owned five homes, including a 2,200-acre ranch in Southern California, where he collected longhorn cattle and horses, along with orchids and works of art. He served as co-chair of the Joffrey Ballet Company. At the height of his financial influence, however, Mr. Murdock suffered grievous losses. Less than a year after losing his wife to cancer in 1985, his oldest son, Eugene, 23, drowned in the pool at the family's estate in Beverly Hills. Mr. Murdock's second son, David II, was killed at age 36 in a car crash on the Santa Monica Freeway in 2004. Mr. Murdock leaves his youngest son, Justin, and a granddaughter. This article originally appeared in

Business Insider

4 days ago

• Business Insider

Castle Biosciences enters collaboration, license agreement with SciBase

Castle Biosciences (CSTL) announced that it has entered into a collaboration and license agreement with SciBase utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis. Under the collaboration and license agreement, the companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of $5M when Castle sales reach $50M annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments.

Yahoo

11-06-2025

• Yahoo

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will explore the challenges precision medicine companies face in commercializing innovative diagnostic tests and discuss strategies for navigating today's market complexities while remaining focused on improving care for patients. Panel Details:Title: Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to EntryDate & Time: Tuesday, June 17, 2025, from 11 a.m.-12 p.m. Eastern TimeLocation: Room 251Focus Area: Diagnostics and Personalized MedicineSession Type: Breakout Session Moderator: Michael Ryan, J.D., Partner, McDermott Will & EmeryPanel Participants: Mara Aspinall, Partner, Illumina Ventures Gillian Hooker, Ph.D., ScM, CGC, Chief Scientific Officer, Concert Derek Maetzold, Founder, President and CEO, Castle Biosciences Castle is also a member of the City of Phoenix and Texas delegations attending BIO 2025. For information on Castle, please visit the City of Phoenix Pavilion (1639) or the Texas Pavilion (2665). To register to attend BIO 2025, visit About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc.